Volixibat potassium ethanolate hydrate

N/A

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameVolixibat potassium ethanolate hydrate
Drug Alias NameVolixibatum伏昔巴特Volixibat沃立昔巴SHP-626 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIleal bile acid transporter inhibitors
TargetsIleal bile acid transporter
Therapy Area/IndicationsPruritusMetabolic Dysfunction-Associated Steatotic Liver DiseaseCholangitis, Sclerosing +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[18] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesLumena Pharmaceuticals IncMirum Pharmaceuticals IncHalo Pharmaceutical Canada Inc +[4] 
Inactive CompaniesN/A
Active IndicationsPruritusCholangitis, SclerosingLiver Cirrhosis, Biliary
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseCholestasis

Other Information

ATC CodeN/A
Related LinksWikipedia